HER2+ Breast Cancer | Specialty

Emerging Role of Abemaciclib for HR+ Advanced Breast Cancer

February 22nd 2017

Ribociclib for HR+ Advanced Breast Cancer

February 22nd 2017

FALCON Trial Data in HR+ Metastatic Breast Cancer

February 22nd 2017

Breast Cancer: Extended Adjuvant Endocrine Therapy

February 22nd 2017

Comparison of Prognostic Tests in Breast Cancer

February 22nd 2017

Breast Cancer: Genomic Testing

February 22nd 2017

MINDACT Trial Design and Results in Breast Cancer

February 22nd 2017

Breast Cancer: Genomic Testing for Adjuvant Therapy

February 22nd 2017

Dr. White on CNS Metastases in HER2+ Breast Cancer

February 22nd 2017

Julia White, MD, The Ohio State University Comprehensive Cancer Center, discusses brain metastases in patients with HER2-positive breast cancer.

Dr. Kalinsky on Optical Imaging for HER2+ Breast Cancer

February 21st 2017

Kevin Kalinsky, MD, assistant professor of Medicine at Columbia University Medical Center, discusses the potential advantages of optical imaging for patients with HER2-positive breast cancer.

Dr. Barcenas on Colestipol in Management of Neratinib Side Effects in HER2+ Breast Cancer

February 14th 2017

Carlos Barcenas, MD, assistant professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses managing neratinib-related side effects with colestipol (Colestid).

Dr. White On RTOG 1119 Trial for Breast Cancer

February 9th 2017

Julia White, MD, professor of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, discusses RTOG-1119 trial for patients with breast cancer.

Patient Selection an Important Next Step in HER2+ Breast Cancer

February 4th 2017

Melanie E. Royce, MD, PhD, discusses the recent progress in the landscape of HER2-positive breast cancer and what she envisions future treatment approaches will be for patients.

Dr. Barcenas on Neratinib-Related Diarrhea in HER2+ Breast Cancer

February 4th 2017

Carlos Barcenas, MD, assistant professor, Department of Breast Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, discusses side effects of neratinib in patients with HER2-positive early-stage breast cancer.

Dr. Loibl Discusses GeparSepto Trial in Breast Cancer

February 4th 2017

Sibylle Loibl, MD, PhD, co-chair of the German Breast Group (GBG) and associate professor at the University of Frankfurt, discusses the GeparSepto trial in subgroups of patients with breast cancer.

Dr. Sanft on Sequencing of Treatments for HER2+ Breast Cancer

February 3rd 2017

Tara Sanft, MD, assistant professor of Medicine, medical director of Adult Survivorship for Yale Cancer Center Survivorship Clinic, discusses sequencing of treatments for patients with HER2-positive breast cancer.

Meta-Analysis Highlights Nab-Paclitaxel Activity Across Subgroups of Breast Cancer

February 1st 2017

Treatment with nanoparticle albumin-bound nab-paclitaxel showed encouraging activity across different subgroups of patients with breast cancer, according to the results of a meta-analysis of several clinical trials.

Dr. Royce on Progress Being Made in HER2+ Positive Breast Cancer

February 1st 2017

Melanie E. Royce, MD, PhD, co-director, Protocol Review and Monitoring System, member, Women’s Cancers Research Program, associate professor of Medicine, University of New Mexico Comprehensive Cancer Center, discusses some of the progress currently being made in the field of HER2-positive breast cancer.

Dr. Pegram on Margetuximab Plus Chemo in HER2+ Breast Cancer

February 1st 2017

Mark D. Pegram, MD, director of the Breast Cancer Oncology Program at Stanford Medicine, discusses the ongoing phase II SOPHIA trial, which is comparing the combination of margetuximab plus chemotherapy with trastuzumab (Herceptin) in patients with HER2-positive breast cancer.

Molecular Testing in Breast Cancer to Answer More Questions in 2017

January 31st 2017

Jenny C. Chang, MD, discusses the significance of molecular testing in breast cancer and how it will lead to an improvement in treatment approaches in 2017 and beyond.